Interleukin-18 Secreting Autologous Anti-CD19 CAR T-Cells (huCART19-IL18) in Patients with Non-Hodgkin Lymphomas Relapsed or Refractory to Prior CAR T-Cell Therapy

Post time 2024-5-4 22:39:08

journal：Blood

Authors：Jakub Svoboda; James N. Gerson; Daniel J. Landsburg; Elise A. Chong; Stefan K. Barta; Sunita Dwivedy Nasta; Marco Ruella; Elizabeth O. Hexner; Amy Marshall; Rachel Leskowitz; Megan Four; Joanne Shea; Tina Matlawski; Amanda Cervini; Megan M. Davis; Mercy Gohil; John Scholler; Donald Hasenmayer; Juliana Rojas Amortegui; Andrea Brennan; Gabriela Plesa; Wei-Ting Hwang; David L. Porter; Joseph Fraietta; Stephen J. Schuster; Carl H. June

Published date：2022-11-15

DOI：10.1182/blood-2022-162393

PDF link：https://ashpublications.org/bloo ... ogous-Anti-CD19-CAR

Article link：http://dx.doi.org/10.1182/blood-2022-162393

Article Source：American Society of Hematology。

Remark：

Post time 2024-5-4 22:39:09

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Other] Interleukin-18 Secreting Autologous Anti-CD19 CAR T-Cells (huCART19-IL18) in Patients with Non-Hodgkin Lymphomas Relapsed or Refractory to Prior CAR T-Cell Therapy

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Other] Interleukin-18 Secreting Autologous Anti-CD19 CAR T-Cells (huCART19-IL18) in Patients with Non-Hodgkin Lymphomas Relapsed or Refractory to Prior CAR T-Cell Therapy Copy

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Other] Interleukin-18 Secreting Autologous Anti-CD19 CAR T-Cells (huCART19-IL18) in Patients with Non-Hodgkin Lymphomas Relapsed or Refractory to Prior CAR T-Cell Therapy